Login to Your Account

Theravance Gets $50M Up Front In Deal On Respiratory Diseases

By Kim Coghill

Tuesday, January 7, 2003
Theravance Inc. stands to make up to $545 million in a deal with GlaxoSmithKline plc to pool their respective long-acting beta 2 agonists to develop treatments for respiratory diseases such as asthma and chronic obstructive pulmonary disease. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription